和肽素在不同疾病中的临床应用进展

doi:10.3969/j.issn.1673-8640.2022.03.020

检验医学 ›› 2022, Vol. 37 ›› Issue (3): 291-294.DOI: 10.3969/j.issn.1673-8640.2022.03.020

和肽素在不同疾病中的临床应用进展

毛杰¹, 卢晴晴¹, 李萍², 石盛洁¹, 李菁¹, 邓长娟¹, 谭超超³, 谢小兵²()

1.湖南中医药大学,湖南长沙 410208
2.湖南中医药大学第一附属医院医学检验与病理中心,湖南长沙 410007
3.湖南省人民医院检验科,湖南长沙 430005

收稿日期:2020-10-30 修回日期:2021-10-31 出版日期:2022-03-30 发布日期:2022-05-10
通讯作者: 谢小兵
作者简介:谢小兵,E-mail： xxiaobing888@163.com。
毛杰,男,1986年生,学士,主管检验师,主要从事肿瘤分子生物学相关研究。

Research progress of clinical application of copeptin in different diseases

MAO Jie¹, LU Qingqing¹, LI Ping², SHI Shengjie¹, LI Jing¹, DENG Changjuan¹, TAN Chaochao³, XIE Xiaobing²()

1. Hunan University of Chinese Medicine,Changsha 410208,Hunan,China
2. Department of Medical Laboratory and Pathology Center,the First Hospital of Hunan University of Chinese Medicine,Changsha 410007,Hunan,China
3. Department of Clinical Laboratory,Hunan People's Hospital,Changsha 430005,Hunan,China

Received:2020-10-30 Revised:2021-10-31 Online:2022-03-30 Published:2022-05-10
Contact: XIE Xiaobing

摘要/Abstract

摘要：

和肽素是精氨酸血管升压素（AVP）前体分子的C末端肽,可与AVP等摩尔释放入血,半衰期约为14 d,稳定且易于检测。和肽素其特异性较低,且无器官特异性,但对急性心肌梗死（AMI）、卒中、慢性肾脏病等疾病有较高的阳性预测价值,敏感性较高。文章对和肽素在心血管疾病、肝脏疾病、肾脏疾病、呼吸系统疾病和脑卒中等疾病中的临床应用作一综述。

关键词: 和肽素, 心脑血管疾病, 肝脏疾病, 肾脏疾病, 呼吸系统疾病

Abstract:

Copeptin is the C-terminal peptide of the precursor molecule of arginine vasopressin（AVP）,which can be released into the blood equimolar with AVP by equal molar,and the half-life of it is about 14 d,which is stable and easy to detect. Copeptin has low specificity and no organ specificity,but it has high positive predictive value and high sensitivity for acute myocardial infarction（AMI）,stroke,chronic kidney disease and other diseases. This review focuses on the clinical application of copeptin in cardiovascular disease,liver disease,kidney disease,respiratory disease and stroke.

Key words: Copeptin, Cardiovascular and cerebrovascular diseases, Liver disease, Kidney disease, Respiratory disease

中图分类号:

R446.1

毛杰, 卢晴晴, 李萍, 石盛洁, 李菁, 邓长娟, 谭超超, 谢小兵. 和肽素在不同疾病中的临床应用进展[J]. 检验医学, 2022, 37(3): 291-294.

MAO Jie, LU Qingqing, LI Ping, SHI Shengjie, LI Jing, DENG Changjuan, TAN Chaochao, XIE Xiaobing. Research progress of clinical application of copeptin in different diseases[J]. Laboratory Medicine, 2022, 37(3): 291-294.

参考文献 25

[1]	TASNEEM M, MANNIX C, WONG A, et al. Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?[J]. World J Nephrol, 2018, 7(2):51-57. DOI URL
[2]	HARPER K M, KNAPP D J, CRISWELL H E, et al. Vasopressin and alcohol:a multifaceted relationship[J]. Psychopharmacology(Berl), 2018, 235(12):3363-3379. DOI URL
[3]	PAMUKCU H E, FELEKOLU M A, ALGÜL E, et al. Copeptin levels predict left ventricular systolic function in STEMI patients:a 2D speckle tracking echocardiography-based prospective observational study[J]. Medicine(Baltimore), 2020, 99(50):e23514.
[4]	韦有全, 黄海清. 血管加压素的心血管效应与临床应用研究进展[J]. 中国医学创新, 2018, 15(2):139-144.
[5]	王琦, 校建波, 李海荣, 等. 急性心肌梗死并发心源性休克与血管紧张素、儿茶酚胺、血管加压素的关系分析[J]. 疑难病杂志, 2018, 17(10):1081-1084.
[6]	方晓君. 血管加压素使用时机和脓毒性休克的死亡率:队列研究[J]. 创伤与急诊电子杂志, 2016, 4(2):123.
[7]	李津健. 血浆和肽素及cTn Ⅰ检测在急性冠状动脉综合征诊断中的应用价值分析[J]. 医学理论与实践, 2019, 32(5):732-733.
[8]	PEDERSEN C K, STENGAARD C, SØNDERGAARD H, et al. A multicentre,randomized,controlled open-label trial to compare an accelerated rule-out protocol using combined prehospital copeptin and in-hospital high sensitive troponin with standard rule-out in patients suspected of acute myocardial infarction-the AROMI trial[J]. Trials, 2018, 19(1):683. DOI URL
[9]	SHIN H, JANG B H, LIM T H, et al. Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction:a systematic review and meta-analysis[J]. PLoS One, 2018, 13(7):e0200379. DOI URL
[10]	JEONG J H, SEO Y H, AHN J Y, et al. Performance of copeptin for early diagnosis of acute myocardial infarction in an emergency department setting[J]. Ann Lab Med, 2020, 40(1):7-14. DOI URL
[11]	MORAWIEC B, PRZYWARA-CHOWANIEC B, MUZYK P, et al. Combined use of high-sensitive cardiac troponin,copeptin,and the modified HEART score for rapid evaluation of chest pain patients[J]. Dis Markers, 2018, 2018:9136971.
[12]	KERBERT A J C, VERSPAGET H W, NAVARRO À A, et al. Copeptin in acute decompensation of liver cirrhosis:relationship with acute-on-chronic liver failure and short-term survival[J]. Crit Care, 2017, 21(1):321. DOI URL
[13]	BARCHETTA I, ENHÖRNING S, CIMINI F A, et al. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity[J]. BMC Med, 2019, 17(1):85. DOI URL
[14]	POPOVIC M, EBRAHIMI F, URWYLER S A, et al. The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome[J]. Endocr Connect, 2020, 9(7):715-723. DOI URL
[15]	KIM J S, YANG J W, CHAI M H, et al. Copeptin in hemodialysis patients with left ventricular dysfunction[J]. Yonsei Med J, 2015, 56(4):976-980. DOI URL
[16]	AFSAR B. Pathophysiology of copeptin in kidney disease and hypertension[J]. Clin Hypertens, 2017, 23:13. DOI URL
[17]	EL BOUSTANY R, TASEVSKA I, MEIJER E, et al. Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population[J]. JCI Insight, 2018, 3(13):e121479. DOI URL
[18]	GANSEVOORT R T, VAN GASTEL M D A, CHAPMAN A B, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease[J]. Kidney Int, 2019, 96(1):159-169. DOI URL
[19]	SCHOEN T, HOHMANN E M, VAN DER LELY S, et al. Plasma copeptin levels and ambulatory blood pressure characteristics in healthy adults[J]. J Hypertens, 2015, 33(8):1571-1579. DOI URL
[20]	BHANDARI S S, LOKE I, DAVIES J E, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals[J]. Clin Sci(Lond), 2009, 116(3):257-263. DOI URL
[21]	ABBASI A, CORPELEIJN E, MEIJER E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes:the Prevention of Renal and Vascular Endstage Disease(PREVEND) study[J]. Diabetologia, 2012, 55(7):1963-1970. DOI URL
[22]	CHOI K S, KIM H J, CHUN H J, et al. Prognostic role of copeptin after stroke:a systematic review and meta-analysis of observational studies[J]. Sci Rep, 2015, 5:11665. DOI URL
[23]	陈加平, 徐令奇, 谭彩萍, 等. 血浆和肽素水平与急性脑梗死患者病情及近期预后的关系分析[J]. 临床和实验医学杂志, 2019, 18(5):489-492.
[24]	许安春, 熊大迁, 江梦曦, 等. 和肽素、PCT、CRP和NLR检测对慢性阻塞性肺疾病伴呼吸衰竭患者的诊断价值[J]. 检验医学与临床, 2020, 17(22):3298-3300.
[25]	胡诗礼, 李丽华, 张李, 等. 血清IL-17和CHE及和肽素水平与老年 COPD合并肺部感染的相关性[J]. 中华医院感染学杂志, 2020, 30(21):3272-3276.

和肽素在不同疾病中的临床应用进展

Research progress of clinical application of copeptin in different diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

[1]	张水检, 周琰, 邵文琦, 张春燕, 潘柏申, 王蓓丽, 郭玮. 半定量干化学法检测尿白蛋白/肌酐比值的临床应用价值[J]. 检验医学, 2022, 37(5): 463-465.
[2]	俞联春, 周君玲. 血糖、血脂在老年人群5年内心脑血管疾病发病风险评估中的作用[J]. 检验医学, 2022, 37(4): 370-373.
[3]	梁涛, 刘凤, 张德太, 王琳, 胡丽华. 武汉地区表观健康人群脂蛋白相关磷脂酶A2水平调查[J]. 检验医学, 2020, 35(9): 889-894.
[4]	张弢, 刘琴, 刘爱平, 丁耀东. NLR和PLR与高脂血症的相关性分析[J]. 检验医学, 2020, 35(8): 767-770.
[5]	陈旭, 冯娟综述, 胡晓波, 王昌富审阅. 假尿嘧啶核苷作为肾病和肿瘤生物标志物的研究进展[J]. 检验医学, 2019, 34(9): 864-867.
[6]	王胜奎, 周俊. 小而密低密度脂蛋白胆固醇在心脑血管系统相关疾病中的意义[J]. 检验医学, 2019, 34(1): 19-22.
[7]	王璐, 李汉华, 张敏, 赵美芸, 蔡慧萍, 李智, 钱朵朵, 吴亚洲. 慢性肾脏疾病生化检测项目的风险评估[J]. 检验医学, 2017, 32(11): 958-961.
[8]	李蕊, 杨柳, 苏明权, 郝晓柯, 马越云. MTHFR基因多态性及血浆同型半胱氨酸水平与心脑血管疾病的相关性分析[J]. 检验医学, 2016, 31(10): 922-924.
[9]	郭玮, 潘柏申. 从K/DOQI 2002到KDIGO 2012慢性肾脏疾病诊疗指南中实验室检测项目相关应用建议的解读[J]. 检验医学, 2015, 30(7): 663-667.
[10]	吴萍, 叶伟民, 李晨, 夏晓红, 张振成, 赵文静, 崔艳芳, 张彩英, 仲人前, 杨再兴. 人附睾蛋白4对慢性肾脏疾病的诊断价值研究[J]. 检验医学, 2015, 30(5): 461-464.
[11]	程清. 脂蛋白相关磷脂酶A2和同型半胱氨酸水平与动脉粥样硬化性心脑血管疾病关系的研究[J]. 检验医学, 2015, 30(1): 40-43.
[12]	李蓉，王华斌，刘蕊，崔小璠，潘文洁. 2型糖尿病患者微量白蛋白尿临界值的研究[J]. 检验医学, 2014, 29(4): 319-323.
[13]	袁锦可. 血清和肽素在扩张型心肌病心力衰竭患者诊断及治疗中的作用[J]. 检验医学, 2013, 28(7): 563-566.
[14]	王永卿;吴婵娟;姚敏;张应爱;郑玲玲. 黎族心脑血管疾病患者apo E基因多态性分析[J]. 检验医学, 2012, 27(4): 308-310.
[15]	黎明;阿祥仁;王立萍. 高原地区不同肝病患者血清总胆汁酸检测结果分析[J]. 检验医学, 2011, 26(08): 526-526.